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Matrix metalloproteinases (MMPs) have been implicated in multiple
physiological and pathological processes related to extracellular
matrix turnover, such as normal growth and development, wound
healing, angiogenesis, joint destruction in arthritis, and tumour inva-
sion and metastasis (Woessner, 1991; Stetler-Stevenson et al, 1993;
Birkedal-Hansen et al, 1995; Crawford and Matrisian, 1996; Nagase,
1996). In the MMP family, the gelatinases [gelatinase A (MMP-2)
and gelatinase B (MMP-9)] are thought to play major roles in the
invasive and metastatic behaviour of cancer cells because of their
ability to cleave the helical domain of type IV collagen, a principal
structural component of the basement membrane (Stetler-Stevenson
et al, 1993; Dickson et al, 1994). However, invasion also requires that
tumour cells traverse the extracellular matrix, which is composed
primarily of collagens type I and III. The collagenases [interstitial
collagenase (collagenase-1, MMP-1), neutrophil collagenase (MMP-
8), collagenase-3 (MMP-13) and MT1-MMP] are the only members
of the metalloproteinase family able to digest collagen type I at
neutral pH (Jeffrey, 1986; Ohuchi et al, 1997). Furthermore, bone,
which is composed principally of collagens type I and III, is one of
the most common sites of metastasis in breast cancer (Sugarbaker et
al, 1981). Thus, the processes of tumour invasion and metastasis
include the degradation of collagen by collagenase-1.
Stromal cell production of MMPs has been implicated as the
major contributor to overall tumour metalloproteinase activity
(Crawford and Matrisian, 1994; MacDougal and Matrisian, 1995).
Although collagenase-1 has been associated with stromal cells in
some breast cancers (Heppner et al, 1996; Dickson et al, 1994),
this enzyme is also constitutively secreted from several tumour
cells, including highly invasive and metastatic breast cancer cell
lines, such as the oestrogen-receptor-negative MDA231 cells
(Templeton et al, 1990). This finding indicates that the tumour
cells, themselves, can contribute to their own invasiveness, and
suggests that decreasing collagenase-1 production by these cells
may decrease their invasive potential.
The vitamin A analogues, all-trans-retinoic acid and the
synthetic retinoids, inhibit transcription of the collagenase gene by
binding to nuclear receptors, the retinoic acid receptors (RARs)
and retinoid X receptors (RXRs) (Mangelsdorf et al, 1994, 1995;
Schroen and Brinckerhoff, 1996a), each with subtypes classified
as a, band g. The RARs/RXRs display specific patterns of expres-
sion throughout development, and contribute to the process of cell
growth and differentiation (Mangelsdorf et al, 1994; Schroen
and Brinckerhoff, 1996a). Additionally, they prevent chemically
induced carcinogenesis in experimental animals (Moon et al,
1992; Anzano et al, 1994) and inhibit proliferation of a variety of
normal and neoplastic cell types in vitro (Lotan et al, 1980). More
recently, the effectiveness of retinoids in the treatment and preven-
tion of a number of human cancers, including breast cancer, has
been established (Castaigne et al, 1990; Costa, 1993; Pastorini et
al, 1993; Hong and Lippman, 1995; Lippman et al, 1995).
Previously, we demonstrated that the inhibition of collagenase-1
synthesis in fibroblasts treated with RA occurs at the transcriptional
level (reviewed in Vincenti et al, 1996; Schroen and Brinckerhoff,
1996a; Benbow and Brinckerhoff, 1997). This inhibition is mediated
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SummaryIn the present study, we investigated the mechanisms controlling constitutive transcription of collagenase-1 and its repression by
all-trans-retinoic acid (RA) in the highly invasive metastatic and oestrogen-receptor-negative breast cancer cell line MDA231. A combination
of in vivo and in vitro experiments that include DNAase I hypersensitivity assays, transient transfection of collagenase-1 promoter constructs,
and electrophoretic mobility shift assays implicate several PEA3 sites, binding sites for Ets-related transcription factors, in the constitutive
expression of the human collagenase-1 promoter. Transient transfection of promoter constructs linked to the luciferase reporter, along with gel
retardation assays, revealed that repression of collagenase-1 transcription by RA is not dependent on the proximal AP-1 site, but, rather,
requires sequences located in distal regions of the promoter. Transcriptional analyses and electrophoretic mobility shift assays suggest that
the PEA3 site located at –3108bp facilitates, at least in part, the transcriptional repression of the human collagenase-1 gene in MDA231 cells.
We conclude that collagenase-1 repression in MDA231 cells occurs by a novel regulatory pathway that does not depend on the proximal AP-
1 site at –73bp, but does depend on distal regions in the collagenase-1 promoter.
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Medical School, Hanover NH 03755, USAthrough a variety of mechanisms that involve the activator protein 1
(AP-1) site at ~ –70 bp (Lafyatis et al, 1990; Schule et al, 1991; Pan
et al, 1992, 1995; Schuchard et al, 1993; Schroen and Brinckerhoff,
1996b; Caelles et al, 1997). To determine whether retinoids exert
similar effects in breast cancer cells, we investigated the role of all-
trans-retinoic acid (RA) on the repression of collagenase-1 in the
oestrogen-receptor-negative MDA231 breast carcinoma cells, a cell
line that is resistant to the growth inhibitory effects of retinoid treat-
ment (Sheikh et al, 1994).
We report that (1) constitutive expression of collagenase-1 in
MDA231 cells correlates with several PEA3 sites in the distal
promoter, (2) repression of collagenase-1 by RA does not depend on
the proximal AP-1 site and (3) repression by RA is mediated, at least
in part, by a PEA3 site located at –3.108 bp. Our data suggest that,
compared with fibroblasts, RA-mediated repression of the collage-
nase-1 gene in MDA231 cells occurs by a novel mechanism.
MATERIALS AND METHODS
Cell culture and Western analysis
The human breast cancer cell line MDA231 was provided by Dr
Lance Liotta at the NIH, Bethesda, MD, USA. Cell cultures were
propagated in Dulbecco’s modified Eagle medium (DMEM;
Gibco), supplemented with 10% fetal calf serum (FCS; Gibco),
penicillin (100 U ml–1) and streptomycin (100 mg ml–1). At conflu-
ency, cells were washed with Hanks’ balanced salt solution
(HBSS; Gibco) and incubated with or without all-trans-retinoic
acid (RA; Sigma; 10–6 M) in the presence of DMEM and lactal-
bumin hydrosylate (LH; 0.20%). This concentration of RA inhibits
collagenase-1 synthesis in fibroblasts and human tumour cells
(Pan et al, 1992; Agadir et al, 1997). Culture medium (1 ml) was
precipitated with 0.5 ml of 10% trichloroacetic acid (TCA) for
30 min on ice. Proteins were pelleted and resuspended in sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
sample buffer, electrophoresed on 7.5% SDS-PAGE minigels,
transferred to Immobilon-P membranes (Millipore, Bedford, MA,
USA) using a Trans-Blot Cell (BioRad). Collagenase protein was
detected as previously described (Rutter et al, 1997). Briefly, the
membranes were blocked for 1 h with 10% FCS, then probed
overnight with anti-(human) collagenase antibody at a dilution of
1:10.000. The membranes were then washed and specific antibody
binding was detected using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA).
Northern analysis
Total cellular RNA was isolated using Trizol LS Reagent (Gibco).
Briefly, cells were scraped from the plates, pelleted and lysed in
Trizol LS Reagent. After chloroform extraction, the RNA was
recovered by precipitation with isopropanol. Total RNA was quan-
titated by optical density, and 10 mg of RNA was subjected to
Northern analysis as previously described (Sambrook et al, 1989).
Northern blots were hybridized with an [a-32P]dCTP-labelled
probe for 20 h at 56°C (0.2 ´ SSC, 0.5% SDS). Blots were washed
twice at room temperature with 2 ´ SSC, followed by two 30-min
washes at 56°C (0.2 ´ SSC, 0.5% SDS) and autoradiographed. The
human collagenase probe and probes for RARs, RXR-a and AP-1
family members have been described previously (Pan et al, 1992;
White and Brinckerhoff, 1995). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a loading control.
Transfection and luciferase assays
The reporter plasmids cloned into the PXP2 luciferase vector have
been described previously (Rutter et al, 1997). Plasmid DNA was
prepared using the Qiagen maxiprep kit (Qiagen). The plasmids
were transiently transfected using Lipofectamine (Gibco). Briefly,
cells were plated at 1.75 ´ 105 in six-well cluster plates in DMEM
containing 10% FCS. The following day, the cells were transfected
with 5 mg DNA and 5 ml Lipofectamine per plate. After 5 h, 1 ml
of DMEM containing 20% FCS was added. After 18 h, the cells
were washed three times with HBSS and incubated in serum-free
DMEM/LH medium alone or in the presence of 1 ´ 10–6 M RA.
Cell lysates were harvested 24 h after treatment and luciferase
activity was determined using a temperature controlled lumi-
nometer as described previously (Rutter et al, 1997). The values
were normalized to the protein content of the harvested lysate
using a modification of the Lowery Assay (DcProtein Assay,
BioRad, Melville, NY, USA). Each transfection was carried out in
triplicate; each plasmid was transfected in at least four separate
experiments using different DNA preparations. Transfection effi-
ciency was determined by Hirt’s analysis (Ausuble et al, 1987;
Sambrook et al, 1993; White and Brinckerhoff, 1995).
DNAase I hypersensitivity assays
DNAase I hypersensitivity assays were performed on nuclei
isolated from untreated cells as described previously (Lowrey et
al, 1992). Nuclei (200 mg DNA per reaction) were digested in a
total volume of 200 ml with DNAase I at 0, 0.1, 0.25, 0.5, 1.0, 1.5
and 2.0 mg ml–1. Reactions were performed at 37°C for 10 min.
For Southern blotting, genomic DNA was digested with HindIII
and XbaI. This digestion releases a 4.6-kb genomic fragment
which has the same 5¢ end as the full-length promoter construct. A
120-bp  EcoRI/XbaI fragment corresponding to the N-terminal
region of the collagenase cDNA (Brinckerhoff et al, 1987) was
used as a probe for Southern blot assays.
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Figure 1 Suppression of collagenase-1 by RA in MDA231 cells. MDA231
cells in DMEM/LH were treated with all-trans-RA (10–6 M) for 18 h. (A) Culture
medium (1 ml) was subjected to TCA precipitation and Western analysis with
sheep antiserum specific to human collagenase-1. (B) Total RNA (10 mg) was
subjected to Northern analysis. The membrane was hybridized with a probe
specific for human collagenase-1, and with GAPDH as loading controlElectrophoretic mobility shift assays (EMSAs)
Oligonucleotides corresponding to human collagenase 5¢ flanking
DNA were used as probes in EMSA assays: PEA3 from –2989/
–3024 (top 5¢-TGAATGGCCATATGTAGGAA GAATACACAC-
CGTGAG-3¢, bottom 5¢-ATTCTTCCTACATATGGCCATTCA-3¢;
AP-1 site from –83/–57 (top 5¢-AAAGCATGAGTCACACAGCC-
CTCCAGCT-3¢, bottom 5¢AGCTGG AGGGCTGTGTGACTCAT-
GCTTT-3¢); PEA3 from –3818/–3852 (top 5¢-TTGGGAGTC-
TGAGGCAGGAACATTGCTTAAGCCCA-3¢, bottom 5¢-TGGG-
CTTAAGCAATGTTCCTGCCTCAGACTCCCAA-3¢); nonspecific
oligonucleotide [top, 5¢ AGCTTGCTCAGGCTAT-3¢ and bottom 5¢
ATAGCCTGAGCAAGCT-3¢ (Pan et al, 1992)]. Complementary
strands were annealed and end labelled with (g-32P)ATP using T4
kinase. Labelled oligonucleotides (30. 000 c.p.m.) were incubated on
ice for 30 min with nuclear extracts (5 mg) of untreated or RA-treated
cells in 10 ml binding reaction as described previously (Schroen and
Brinckerhoff, 1996b). Nuclear extracts were harvested after 18 h RA
treatment. The 18-h time point was determined by time course
analysis. Samples were electrophoresed at 150 V on 5% acrylamide
gels under non-reducing conditions, dried and autoradiographed at
–70°C using DuPont autoradiographic film.
RESULTS
All-trans-retinoic acid (RA) suppresses collagenase-1
gene expression in the MDA231 breast cancer cell line
MDA231, a non-oestrogen-dependent breast carcinoma cell line,
expresses collagenase-1 constitutively (Templeton et al, 1990). As
a first step in investigating the mechanism(s) controlling collage-
nase-1 expression in these cells, we confirmed these previous find-
ings. RNA and media were harvested from confluent cells that
were cultured in serum-free conditions for 24 h, with or without
RA (1 ´ 10–6 M). Figure 1 demonstrates that in these MDA231
cells (1) collagenase-1 mRNA is produced constitutively, (2) RA
represses both collagenase-1 mRNA and protein and (3) levels of
collagenase protein correlate with levels of collagenase-1 mRNA
(Vincenti et al, 1996). Densitometric quantification of mRNA and
protein revealed a 55% and 51% decrease respectively (data not
shown). In addition, in agreement with Sheikh et al (1994), RA at
a concentration of 1 ´ 10–6 M was not cytotoxic and had no effect
on cell proliferation (data not shown).
All-trans-retinoic acid induces expression of RAR-b,
but does not affect the expression of other RARs/RXRs
or of AP-1 binding proteins in MDA231 cells
It has previously been demonstrated that RA is a negative regu-
lator for AP-1 responsive genes (Nicholson et al, 1990; Schule
et al, 1991; Yang-Yen et al, 1991; Pan et al, 1992; Schroen and
Brinckerhoff, 1996a). Several mechanisms may account for the
interference of AP-1 activity by RA. First, RA decreases FOS and
JUN mRNA levels in rabbit fibroblasts (Lafyatis et al, 1990, Pan
et al, 1992), whereas increasing mRNA levels for RARs and RXRs
(Pan et al, 1995). Second, RAR/RXRs may bind directly to
FOS/JUN and sequester the AP-1 proteins (Nicholson et al, 1990;
Schule et al, 1991; Salbert et al, 1993); third, nuclear hormone
receptors antagonize AP-1 by inhibition of the Jun amino-terminal
kinase (JNK) pathway (Caelles et al, 1997).
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Figure 2 Expression of RARs/RXR and AP-1 transcription factors in MDA231 cells. Confluent cultures of MDA231 cells in serum-free DMEM/LH medium,
were left untreated or were treated with RA (10–6 M). At the time points indicated, total RNA was harvested and 20 mg were subjected to Northern analysis.
(A) Time course for the expression of RAR and RXR mRNAs in MDA231 cells. (B) RNA analysis (18 h time points) of members of the fos and jun family of
transcription factors. Control for loading is shown by ethidium bromide staining of 18S and 28S RNAs or by hybridization with a cDNA for GAPDHTherefore, to investigate the possible role of RARs and RXRs
in collagenase-1 repression in MDA231 cells, we performed
Northern analyses to determine the effects of RA on expression of
these receptors (Figure 2A). We found that mRNAs for RAR-a
and RAR-g were constitutively expressed and were not regulated
by RA. RXR-a was not detectable and was not induced by RA. In
contrast, RA increased the steady-state mRNA level for RAR-b
within 4 h, and high levels were maintained over a 24-h period. It
has been reported that, compared with fibroblasts, the expression
of RAR-b is absent or down-regulated in most breast cancer cell
lines (Seewaldt et al, 1995; Pan et al, 1995). We note, however,
that although constitutive levels of RAR-b appear to be lower than
levels of RAR-a or RAR-g in untreated cells, it was induced by
RA, suggesting that RAR-b may play a role in suppression of
collagenase-1 transcription in MDA231 cells. In contrast, the
inability of RA to regulate RAR-a supports the studies by Sheikh
et al (1994) in which dysregulation of RAR-a in these cells was
responsible for the failure of RA to inhibit cell growth.
Because the inhibition of collagenase-1 and of stromelysin-1 by
RA in fibroblasts occurs primarily, but not exclusively, through the
AP-1 site at ~ –70 bp, we examined the effect of RA treatment on
levels of mRNA for members of the AP-1 family of transcription
factors. c-Jun, junB and junD were present constitutively in
untreated cells, whereas c-fos was undetectable, and treatment of
cells with RA for 18 h did not change the level of mRNA for these
AP-1 factors (Figure 2B). These results indicate that repression of
collagenase-1 in MDA231 cells is not mediated by down-regula-
tion of AP-1 binding factors.
Identification of DNAase I hypersensitivity sites in the
collagenase-1 promoter
To determine the regulatory regions in the collagenase-1 promoter
that are involved in the constitutive transcription of collagenase-1
in MDA231 cells, we performed DNAase I hypersensitivity
assays. This in vivo assay is able to detect and localize domains of
altered chromatin structure such as those formed by the binding of
transcription factors to enhancers or promoters, and allows the
screening of large regions of genomic DNA for potential regula-
tory elements (Elder et al, 1990; Stamatoyannopolus et al, 1995).
The pattern of DNAase I digestion of nuclei from untreated cells is
shown in Figure 3A. This assay detected the expected parental
fragment of 4600 bp and four major sub-bands at approximately
–4000 bp, –3000 bp, –2000 bp and –1400 bp. The band at
–1400 bp is also present in the DNAase untreated lane and may,
therefore, not constitute a true hypersensitive site (Lowrey et al,
1992), even though transcriptional studies suggest otherwise (see
below). Alignment of the regions identified by DNAase I treat-
ment with the 4372-bp human collagenase-1 promoter sequence
reveals the presence of several PEA3 sites (5¢-C/AGGAA/TG-3¢)
(Figure 3B), which bind members of the Ets family of transcrip-
tion factors (Gutman and Wasylyk, 1990). Because PEA3 sites at
–3108 bp and –3882 bp are localized in a region of the promoter
that is devoid of other known cis-acting elements (Rutter et al,
1997), it is possible that these sites contribute to constitutive tran-
scription of the collagenase-1 promoter.
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Figure 3 Identification of hypersensitivity sites in the human collagenase-1
promoter. Increasing amounts of DNAase I was added from left to right. (A)
DNAase I hypersensitivity sites in the human collagenase-1 promoter
associated with basal transcription in MDA231 cells are indicated by arrows.
The band marked with an asterisk (*) may not denote a true hypersensitive
site because this band is also present in the absence of DNAase I (lane 1).
(B) Location of the various AP-1 and PEA3 sites throughout the
collagenase-1 promoter
Figure 4 Constitutive transcription of the human collagenase-1 promoter
and RA repression of promoter activity in MDA231 cells. MDA231 cells were
transiently transected with 5 mg of the indicated promoter constructs together
with 5 ml LipofectAmine, added to each well of 1.75´105 cells in DMEM/LH.
Cells were harvested after 18 h and luciferase activity was read on an
ML2250 Microtiter Plate Luminometer (Dynatech Laboratories). Activity is
expressed as relative light units (RLUs). Each transfection was carried out in
quadruplicate. Error bars represent the standard deviation of the mean. The
increase in constitutive expression seen with the 512-bp vs the 125-bp
construct was very significant (DDP < 0.0054) or extremely significant
(DDDP < 0.0003) when compared with the 3300-bp construct. RA treatment
resulted in a very significant repression of collagenase-1 transcription
(**P < 0.0061 for 1600-bp promoter construct) and a significant repression
(*P < 0.014) for the 3300-bp construct when compared with the 125-bp
construct
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To further define regions of the collagenase-1 promoter that partic-
ipate in constitutive transcription, we used transient transfection
of a series of collagenase-1 promoter fragments linked to the
luciferase reporter gene. The smallest construct (125 bp),
containing an AP-1 site at –73 bp and a PEA3 site at –88 bp,
displays only minimal activity (Figure 4). A 6.5-fold increase in
activity (DDP < 0.0054) was observed between 125 bp and 512 bp.
This increase may be due to the presence of two putative AP-1
sites, at –181 bp and –429 bp of the promoter (Figure 3B; Rutter et
al, 1997). Thus, sequences in the proximal promoter, other than the
AP-1 site at –73 bp, have a role in constitutive transcription.
However, transcription decreased approximately threefold
between 1600 bp and 2900 bp (DDP < 0.0027), a region of the
promoter containing several potential repressor elements (Rutter et
al, 1997). Fragments of 3300 bp or larger showed a sixteenfold
increase in activity over the 125 bp construct, thereby overcoming
the repression observed with the 2900 bp construct. These studies,
together with the DNAase I hypersensitivity data, support the
hypothesis that upstream elements, i.e. PEA3 sites located
between –3000 bp and –4000 bp, play a role in transcriptional
activity of the human collagenase-1 promoter.
We then examined the ability of RA to repress transcription.
Treatment of the cells with RA resulted in significant repression of
the collagenase-1 promoter only with fragments larger than 512 bp
(*P < 0.038) (Figure 3), suggesting that the inhibitory effects of RA
are independent of the proximal AP-1 site. With larger fragments
containing 1600 bp, and 3300 bp of the promoter, a significant
repression of 1.8- and 1.5-fold (**P < 0.0061 and *P < 0.014
respectively) by RA was also observed. Compared with the
1600 bp construct, 2900 bp of the collagenase-1 promoter shows
a sharp decrease in constitutive expression, and treatment with
RA resulted in an additional inhibition of promoter activity of
approximately eightfold. Because this region contains several
silencing elements, it is possible that their function may be
enhanced in the presence of RA. However, most importantly, this
constitutive repression is overcome with larger promoter frag-
ments, indicating the presence of positive regulatory elements that
override the negative ones (Figure 4). The fold of RA repression
observed with these larger constructs, including the 4400-bp frag-
ments was similar to that seen with the 1600-bp construct,
suggesting that the RA responsive element(s) is located upstream of
512 bp in distal regions of the promoter.
The PEA3 site at –3108 bp, but not the AP-1 site, binds
nuclear proteins induced by all-trans-retinoic acid
The inability of RA to suppress AP-1 proteins was further investi-
gated by gel mobility shift analyses (EMSA). We compared the
pattern of nuclear proteins from untreated and RA-treated
MDA231 cells that bound to an oligonucleotide containing the
AP-1 site at –73 bp. In contrast to previous findings in fibroblasts
(Pan et al, 1995), we found that RA treatment of this breast cancer
cell line did not alter the pattern of AP-1 binding proteins (Figure
5A). The inability of RA to alter the complex of nuclear proteins
binding to the AP-1 site supports the hypothesis that this site does
not participate in repression of collagenase-1 activity in the
MDA231 cells. This hypothesis is further strengthened by the data
presented in Figures 3 and 4B, which illustrate that transcription of
a small promoter fragment is not suppressed by RA, and that the
constitutive expression of c-jun, junB and JunD in the MDA231
cells is not altered by RA.
Because our DNAase I hypersensitivity assays and the tran-
scriptional analysis implicated regions in the distal promoter that
contain PEA3 sites in constitutive transcription, we questioned
whether these sites may be involved in repression by RA. We
used EMSA to examine the role of the individual PEA3 sites in
the binding of nuclear extracts from both untreated MDA231
cells or from cells treated with RA. We found specific binding to
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Figure 5 Specific complex formation between nuclear proteins and radiolabelled fragments of the human collagenase-1 promoter. Gel shift analysis of nuclear
proteins and radiolabelled probes containing the (A) AP-1 site at –73 bp, (B) PEA3 site at –3108 bp, and (C) PEA3 site at –3832 bp. Complexes were formed
using 5 mg of nuclear extracts from untreated and RA treated cells with radiolabelled probes as indicated. The arrows in (B) point out a change in the binding
pattern in RA-treated extracts; s, specific oligonucleotide; ns, non-specific oligonucleotide; probe, free probe
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PEA3 –3832 bpoligonucleotides containing a PEA3 site at –88 bp, –1381 bp (data
not shown) and –3832 bp (Figure 5B) by nuclear extracts from
untreated and RA-treated cells. Importantly, however, the binding
pattern did not change when cells were treated with RA. In
contrast, an oligonucleotide encompassing the PEA3 site at
–3108 bp showed an increase in binding activity with extracts
from RA-treated cells. This RA-induced binding could be
completed by self, but not by a non-specific oligonucleotide
(Figure 5C). These findings suggest that the PEA3 site at –3108 bp
may, at least in part, mediate RA repression of collagenase-1 in
MDA231 cells. Similarly, Schneikert et al (1996) reported that
inhibition of collagenase-1 and stromelysin-1 via the androgen
receptor is mediated by members of the Ets family of transcription
factors (see Discussion section).
DISCUSSION
In this study, we investigated the mechanisms controlling constitu-
tive transcription of collagenase-1 and its repression by all-trans-
retinoic acid (RA) in the highly invasive and metastatic breast
cancer cell line MDA231 (Templeton et al, 1990; Bae et al, 1993).
Low constitutive expression of the collagenase-1 promoter was
observed with a small (125 bp) promoter fragment, whereas a
fragment encompassing 512 bp of the promoter showed a signifi-
cant increase in transcriptional activity. This increase may be due
to several AP-1 sites present in the region between –125 bp and
–512 bp (Figure 3B) (Rutter et al, 1997). Possibly, these sites
cooperate with the proximal AP-1/PEA3 elements (Benbow and
Brinckerhoff, 1997), resulting in an increased transcriptional acti-
vation. This transcription may be further enhanced by elements
located in the distal promoter, including PEA3 sites at –1381 bp,
–3108 bp and –3832 bp, whose location correlates with the pattern
of DNAase I hypersensitive sites (Figure 3). We also note that
constitutive transcription of the collagenase-1 promoter was
significantly reduced (DDP < 0.0027) between –1600 and –2900
bp. This region contains several putative silencer elements (Rutter
et al, 1997), which may account for the reduction in activity.
Importantly, however, positive regulatory elements, which reside
5¢ of –2900 bp can overcome this repression, indicating that the
expression of the endogenous collagenase-1 gene is the net total of
positive and negative regulators.
Along with the DNAase I hypersensitivity studies, transient
transfection and gel mobility analyses also implicated a role for a
PEA3 site in the regulation of collagenase-1 in MDA231 cells.
Proteins bound constitutively to these sites, and binding was
specific as shown by competition with a self but not with a non-
specific oligonucleotide. Interestingly, expression of the PEA3
group of Ets-related transcription factors in human breast cancer
cells has been observed (Baert et al, 1997; Benz et al, 1997). These
genes were expressed at high levels in oestrogen-receptor-negative
cells, including MDA231, when compared with oestrogen-
receptor-positive cell lines. These Ets-related transcription factors
are thought to have a potential role in the regulation of growth and
the progression of breast cancer cells, although the target genes for
these transcription factors are not known (Baert et al, 1997). Our
data suggest that the collagenase-1 promoter is a primary target.
The importance of upstream regions in the regulation of the
human collagenase-1 promoter has been shown previously.
Activation of the collagenase-1 gene by interleukin 1b (IL-1b) in
both fibroblasts and BC8701 breast cancer cells is regulated by
regions in the distal promoter (Rutter et al, 1997). In addition,
Doyle et al (1997) reported that the transcriptional induction of
collagenase-1 by PMA in differentiated monocyte-like (U937) cells
is regulated not only by the proximal AP-1 site but also by a distal
CCAAT/enhancer-binding protein-b site (C/EBP-b) located
between –2010 bp and –1954 bp. Thus, it is becoming increasingly
evident that in addition to the proximal AP-1/PEA3 elements, tran-
scriptional regulation of the collagenase-1 gene depends on distal
regions of the promoter (Benbow and Brinckerhoff, 1997).
Treatment of MDA231 cells with RA decreased collagenase-1
mRNA and protein (Figure 1), but did not change the levels of AP-
1 transcription factors as shown by Northern analyses and by
EMSA (Figures 2B and 5A). This observation is in agreement with
work from van der Burg et al (1995), which showed an overall
increase in AP-1 protein activity in hormone-independent human
breast carcinoma cell lines and an inability of RA to repress AP-1
transactivation in the presence of RA. This may be due to the inhi-
bition of the JNK cascade by RARs/RXRs, normally involved in
the activation of AP-1 proteins (Caelles et al, 1997). Further
evidence of AP-1-independent repression by RA in the MDA231
cells comes from the transfection data (Figure 4), which indicate
that expression of a minimal promoter (125 bp) is not altered by
RA, and from the observation that the binding of nuclear proteins
to an oligonucleotide containing the proximal AP-1 was not
affected by RA treatment (Figure 5A). However, RA repression
does correlate with regions located in more distal regions of the
promoter, including an element(s) between –512 bp and –1600 bp
and the PEA3 element at –3108 bp (Figures 4 and 5B). Although
the region between –3462 bp and –4054 bp of the collagenase
promoter contains a number of putative silencer elements, the
region between –2972 bp and –3462 bp contains only a cyclic
AMP responsive element-binding protein (CREB) binding site, in
addition to the PEA3 element at –3108 bp (Rutter et al, 1997). It is
possible, therefore, that the presence of these silencers allows
constitutive binding of proteins to the PEA3 site at –3832 bp, but
does not allow the interaction of additional regulatory proteins
due, perhaps, to steric hindrance.
In contrast to our findings, Agadir et al (1997) reported that
retinyl methyl ether (RME) and RA down-regulate transcription of
AP-1 activity induced by phorbol esters and growth factors in
human breast cancer cells. The discrepancy may be explained by
the fact that our studies were conducted in the context of a full-
length collagenase-1 promoter, rather than with an isolated AP-1
site. Furthermore, Agadir et al (1997) induced AP-1 activity by
treatment with phorbol esters, and treatment with RA may have
sequestered this activity (Schroen and Brinckerhoff, 1996b).
Although we did not see a change in AP-1 binding activity after
RA treatment, we did observe that RA treatment increased the
binding activity to an oligonucleotide spanning the PEA3 site at
–3108 bp. Studies from Wasylyk et al (1992) pointed out that
nucleotides adjacent to the core PEA3 site (GGA) can influence
which proteins can bind to this site and, thus, it is likely that these
adjacent sequences permit differential binding of proteins to the
PEA3 site at –3108 bp vs. the site at –3832 bp. Nonetheless, we
were not able to identify the proteins bound to the –3108 bp site,
perhaps because of the limitations of antibodies available.
However, in support of our findings, Schneikert et al (1996)
reported that androgen negatively regulates the expression of
several MMPs, including collagenase-1, in prostate cancer cells.
Sequences in the collagenase-1 gene that mediate this effect did
not encompass the regulatory AP-1 site at –73 bp but, rather,
depended on a motif that binds ERM, a member of the Ets family
226 U Benbow et al
British Journal of Cancer (1999) 79(2), 221–228 © Cancer Research Campaign 1999of transcription factors. Thus, their findings set a precedent for
non-AP-1-mediated repression of MMP gene expression by RA
and our data support this concept.
High levels of expression of the Ets-related proteins, ERM and
ER81, are present in MDA231 and other oestrogen-receptor-
negative aggressive cell lines. They are not, however, present in
oestrogen-receptor-positive cell lines such as MCF-7 cells (Baert
et al, 1997), suggesting that this family of proteins has a role in
the regulation of tumour progression in breast cancer. Indeed,
Higashimo et al (1995) reported that the Ets-related protein E1A-F
differentially activates matrix metalloproteinase promoters,
including collagenase-1, and confers an invasive phenotype in
human breast cancer cells (Kaya et al, 1996), which can be
reversed by expression of antisense E1A-F (Hida et al, 1997). In
addition to its effect on MMP expression, PEA3 sites influence the
expression of other genes in mammary tumours. For example, a
PEA3 site participates in the activation of the vimentin promoter
in MDA231 whose gene product, in turn, contributes to the
metastatic potential of mammary tumours (Chen et al, 1996).
Inhibition of collagenase-1 transcription by RA has been shown
to be ligand dependent and to require RAR homodimers
(Nicholson et al, 1990; Schule et al, 1991) and RAR/RXR
heterodimers (Pan et al, 1995). In MDA231 cells, RA induces
RAR-b but does not affect the expression of RAR-a and RAR-g,
which is constitutive. These findings are in agreement with others
who have observed that RAR-a and RAR-g are not regulated by
RA in several human breast cancer cell lines (Roman et al, 1992),
suggesting that RAR-b may be a key player in RA-mediated
repression of collagenase-1 in MDA231 breast cancer cells. One
possibility may be that, in the presence of ligand, the binding of
RARs/RXRs to Ets-related proteins converts a potential inducer of
MMP gene expression to a negative regulator, as seen with ERM
in the presence of the androgen receptor (Schneikert et al, 1996).
In summary, the RA-mediated negative regulation of collage-
nase-1 described in this paper suggests that the mechanism(s)
controlling this repression in the MDA231 breast cancer cell line
differs from that observed in fibroblasts, but may resemble the
steroid-hormone-mediated repression of collagenase-1 in prostate
cancer cells. These mechanisms implicate PEA3 sites, rather than
AP-1 sites, as major players. Thus, the AP-1 independent repres-
sion of collagenase-1 by RA implies a new repertoire of possibili-
ties by which MMP gene expression is regulated in a cell and/or
tissue-specific fashion. Our data also suggests that the therapeutic
effects of retinoids may be beneficial in oestrogen-receptor-nega-
tive cell lines by inhibiting collagenase-1 expression, thereby
limiting the degradation of the extracellular matrix that is associ-
ated with tumour invasion (Dickson et al, 1994; Ohishi et al, 1995).
ACKNOWLEDGEMENTS
This study was supported by NIH, AR-26599 and the RGK
Foundation (to CEB), NIH, HL-52243 (to CHL), and by fellowships
from NIH: T32-CA-09658 and NRSA 1F32-AR-08437 (to UB).
REFERENCES
Agadir A, Shealy YF, Hill DL and Zhang X (1997) Retinyl methyl ether down-
regulates activator protein 1 transcriptional activation in breast cancer cells.
Cancer Res 57: 3444–3450
Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB and
Sporn MB (1994) Prevention of breast cancer in the rat with 9-cis-retinoic acid
as a single agent and in combination with tamoxifen. Cancer Res 54: 4614–4617
Ausuble FF, Brent R, Kingston RE, Moore DDS JG, Smith JA and Struhl K (1987)
Current Protocols in Molecular Biology. Greene and Wiley Interscience: New
York
Bae SN, Arand G, Azzam H, Pavasant P, Torri J, Frandsen TL and Thompson EW
(1993) Molecular and cellular analysis of basement membrane invasion by
human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res
Treat 24: 241–255
Baert JL, Monte D, Musgrove EA, Albagli O, Sutherland RL and de Launoit Y
(1997) Expression of the PEA3 group of ETS-related transcription factors in
human breast-cancer cells. Int J Cancer 70: 590–597
Benbow U and Brinckerhoff CE (1997) The AP-1 Site and MMP gene Regulation:
what Is All the Fuss About? Matrix Biol 15: 519–526
Benz CC, O’Hagan RC, Richter B, Scott GK, Cang CH, Xiong X, Chew K, Ljung
BM, Edgerton S, Thor A and Hassell JA (1997) HER2/Neu and Ets
transcription activator PEA3 are coodinately upregulated in human breast
cancer. Oncogene 15: 1513–1525
Birkedal-Hansen H (1995) Proteolytic remodeling of extracellular matrix. Curr
Opinions Cell Biol 7: 728–735
Brinckerhoff CE, Ruby PL, Austin SD, Fini ME and White HD (1987) Molecular
cloning of human synovial cell collagenase and selection of a single gene from
genomic DNA. J Clin Invest 79: 542–546
Caelles C, Gonzalez-Sancho JM and Munoz A (1997) Nuclear hormone receptor
anatgonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11:
3351–3364
Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P and Degos L
(1990) All-trans retinoic acid as a differentiation therapy for acute
promyelocytic leukemia. I. Clinical results (see comments). Blood 76:
1704–1709
Chen JH, Vercamer C, Li Z, Paulin D, Vandenbunder B and Stehelin D (1996) PEA3
transactivates vimentin promoter in mammary epithelial and tumor cells.
Oncogene 13: 1667–1675
Costa A (1993) Breast cancer chemoprevention. Eur J Cancer 29A: 589–592
Crawford HC and Matrisian LM (1994) Tumor and stromal expression of matrix
metalloproteinases and their role in tumor progression. Invasion Metastasis 14:
234–245
Crawford HC and Matrisian LM (1996) Mechanisms controlling the transcription of
matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein
49: 20–37
Dickson RB, Shi YE and Johnson MD (1994) Matrix-degrading proteases in
hormone-dependent breast cancer. Breast Cancer Res Treat 31: 167–173
Doyle GAR, Pierce RA and Parks WC (1997) Transcriptional induction of
collagenase-1 in differentiated and monocyte-like (U937) cells is regulated by
AP-1 and an upstream CEBP-b site. J Biol Chem 272: 11840–11849
Elder JT, Forrester WC, Thompson C, Mager D, Henthorn P, Peretz M,
Papayannopoulou T and Groudine M (1990) Translocation of an erythroid-
specific hypersensitive site in deletion-type hereditary persistence of fetal
hemoglobin. Mol Cell Biol 10: 1382–1389
Gutman A and Wasylyk B (1990) The collagenase gene promoter contains a TPA
and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites.
EMBO J 9: 2241–2246
Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH (1996) Expression of most
matrix metalloproteinase family members in breast cancer represents a tumor-
induced host response. Am J Pathol 149: 273–282
Hida K, Shindoh M, Yasuda M, Hanzawa M, Funaoka K, Kohgo T, Amemiya K,
Totsuka Y, Yoshida K and Fujinaga K (1997) Antisense E1AF transfection
restrains oral cancer invasion by reducing matrix metalloproteinase activities.
Am J Pathol 150: 2125–2132
Higashino F, Yoshida K, Noumi T, Seiki M and Fujinaga K (1995) Ets-related
protein E1A-F can activate three different matrix metalloproteinase gene
promoters. Oncogene 10: 1461–1463
Hong WK and Lippman SM (1995) Cancer chemoprevention. J Natl Cancer Inst
Monogr 17: 49–53
Jeffrey J (1986) Regulation of Matrix Accumulation. Mecham RP (ed.), pp. 53–98
Academic Press: New York
Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S and Fujinaga K (1996) A single
ets-related transcription factor, E1AF, confers invasive phenotype on human
cancer cells. Oncogene 12: 221–227
Lafyatis R, Kim SJ, Angel P, Roberts AB, Sporn MB, Karin M and Wilder RL
(1990) Interleukin-1 stimulates and all-trans-retinoic acid inhibits collagenase
gene expression through its 5¢ activator protein-1-binding site. Mol Endocrinol
4: 973–980
Lippman SM, Heyman RA, Kurie JM, Benner SE and Hong WK (1995) Retinoids
and chemoprevention: clinical and basic studies. J Cell Biochem (suppl.) 22:
1–10
Retinoic acid repression of collagenase-1 in breast cancer cells 227
British Journal of Cancer (1999) 79(2), 221–228 © Cancer Research Campaign 1999Lotan R (1980) Effects of Vitamin A and its analogs (retinoids) on normal and
neoplastic cells. Biochem Biophys Acta 605: 33–90
Lowrey CH, Bodine DM and Nienhuis AW (1992) Mechanism of DNase I
hypersensitive site formation within the human globin locus control region.
Proc Natl Acad Sci USA 89: 1143–1147
MacDougall JR and Matrisian LM 1995) Contributions of tumor and stromal matrix
metalloproteinases to tumor progression, invasion and metastasis. Cancer
Metastasis Rev 14: 351–362
Mangelsdorf DJ, Umesono K and Evans RM (1994) The retinoid receptors. In The
Retinoids: Biology, Chemistry and Medicine. Sporn MB, Roberts AB and
Goodman DS (eds.), pp. 319–349. Raven Press: New York
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K,
Blumberg B, Kastner P, Mark M and Chambon P (1995) The nuclear receptor
superfamily: the second decade. Cell 83: 835–839
Moon RC, Mehta RG and Detrisac CJ (1992) Retinoids as chemopreventive agents
for breast cancer. Cancer Detect Prev 16: 73–79
Nagase H (1996) Zinc Metalloproteinses in Health and Disease. NM Hopper (ed.),
pp. 153–204. Tayler and Francis: London
Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C and Chambon P (1990)
Negative regulation of the rat stromelysin gene promoter by retinoic acid is
mediated by an AP1 binding site. EMBO J 9: 4443–4454
Ohishi K, Fujita N, Morinaga Y and Tsuruo T (1995) H-31 human breast cancer
cells stimulate type I collagenase production in osteoblast-like cells and induce
bone resorption. Clin Exp Metastasis 13: 287–295
Ohuchi E, Imau K, Fujii, Y and Sato H (1997) Membrane type 1 matrix
metalloproteinase digest interstitial collagenase and other extracellular matrix
macromolecules. J Biol Chem 272: 2446–2451
Pan L, Chamberlain SH, Auble DT and Brinckerhoff CE (1992) Differential
regulation of collagenase gene expression by retinoic acid receptors-alpha, beta
and gamma. Nucleic Acids Res 20: 3105–3111
Pan L, Eckhoff C and Brinckerhoff CE (1995) Suppression of collagenase gene
expression by all-trans and 9-cis retinoic acid is ligand dependent and requires
both RARs and RXRs. J Cell Biochem 57: 575–589
Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N,
Clerici M, Soresi E, Valente M et al (1993) Adjuvant treatment of stage I lung
cancer with high-dose vitamin A (see comments). J Clin Oncol 11: 1216–1222
Roman SD, Clarke CL, Hall RE, Alexander IE and Sutherland RL (1992)
Expression and regulation of retinoic acid receptors in human breast cancer
cells. Cancer Res 52: 2236–2242
Rutter JL, Benbow U, Coon CI and Brinckerhoff CE (1997) Cell-type specific
regulation of human interstitial collagenase-1 gene expression in human
fibroblasts and BC-8701 breast cancer cells. J Cell Biochem 66: 11–15
Salbert G, Fanjul A, Piedrafita FJ, Lu XP, Kim SJ, Tran P and Pfahl M (1993)
Retinoic acid receptors and retinoid X receptor alpha down-regulate the
transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. Mol
Endocrinol 7: 1347–1356
Sambrook J, Fritsch EF and Maniates T (1993) Molecular Cloning: A Laboratory
Manual. Cold Spring Habor Laboratory Press: Cold Spring Harbor, NY
Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y and Cato AC (1996)
Androgen receptor-Ets protein interaction is a novel mechanism for steroid
hormone-mediated down-modulation of matrix metalloproteinase expression.
J Biol Chem 271: 23907–23913
Schroen DJ and Brinckerhoff CE (1996a) Nuclear hormone receptors inhibit matrix
metalloproteinase (MMP) gene expression through diverse mechanisms. Gene
Expression 6: 197–207
Schroen DJ and Brinckerhoff CE (1996b) Inhibition of rabbit collagenase (matrix
metalloproteinase-1; MMP-1) transcription by retinoid receptors: evidence for
binding of RARs/RXRs to the –77 AP-1 site through interactions with c-Jun.
J Cell Physiol 169: 320–332
Schuchard M, Landers JP, Sandhu NP and Spelsberg TC (1993) Steroid hormone
regulation of nuclear proto-oncogenes. Endocr Rev 14: 659–669
Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, Verma IM and
Evans RM (1991) Retinoic acid is a negative regulator of AP-1-responsive
genes. Proc Natl Acad Sci USA 88: 6092–6096
Seewaldt VL, Johnson BS, Parker MB, Collins SJ and Swisshelm K (1995)
Expression of retinoic acid receptor beta mediates retinoic acid-induced growth
arrest and apoptosis in breast cancer cells. Cell Growth Differ 6: 1077–1088
Sheikh MS, Shao ZM, Li XS, Dawson M, Jetten AM, Wu S, Conley BA, Garcia M,
Rochefort H and Fontana JA (1994) Retinoic-resistant estrogen receptor-
negative human breast carcinoma cells transfected with retinoic acid receptor-
alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem 269:
21440–21447
Stamatoyannopoulos JA, Goodwin A, Joyce T and Lowrey CH (1995) NF-E2 and
GATA binding motifs are required for the formation of DNase I hypersensitive
site 4 of the human beta-globin locus control region. EMBO J 14: 106–1016
Stetler-Stevenson WG, Liotta LA and Kleiner Jr DE (1993) Extracellular matrix 6:
role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:
1434–1441
Sugarbaker EV (1981) Patterns of metastasis in human malignancies. In Cancer
Biology Reviews. Marchalonis JJ, Hanna MG, and Fidler IJ, (eds.),
pp. 235–278. Marcel Dekker: New York
Templeton NS, Brown PD, Levy AT, Margulies IM, Liotta LA and Stetler-Stevenson
WG (1990) Cloning and characterization of human tumor cell interstitial
collagenase. Cancer Res 50: 5431–5437
van der Burg B, Slager-Davidov R, van der Leede BM, de Laat SW and van der
Saag PT (1995) Differential regulation of AP1 activity by retinoic acid in
hormone-dependent and -independent breast cancer cells. Mol Cell Endocrinol
112: 143–152
Vincenti MP, White LA, Schroen DJ, Benbow U and Brinckerhoff CE (1996)
Regulating expression of the gene for matrix metalloproteinase-1
(collagenase): mechanisms that control enzyme activity, transcription and
mRNA stability. Crit Rev Eukaryote Gene Expression 6: 391–411
Wasylyk B, Hahn SL and Giovane A (1993) The Ets family of transcrition factors.
Eur J Biochem 211: 7–18
White LA and Brinckerhoff CE (1995) Two AP-1 elements in the collagenase
(MMP-1) promoter have differential effects on transcription and bind JunD,
c-Fos, and Fra-2. Matrix Biol 14: 715–725
Woessner Jr JF (1991) Matrix metalloproteinases and their inhibitors in connective
tissue remodeling. FASEB J 5: 2145–2154
Yang-Yen HF, Zhang XK, Graupner G, Tzukermann M, Sakamoto B, Karin M and
Pfahl M (1991) Anatgonism between retinoic acid receptors and AP-1:
implication for tumor promotion and inflammation. New Biol 3: 1206–1219
228 U Benbow et al
British Journal of Cancer (1999) 79(2), 221–228 © Cancer Research Campaign 1999